Extended interval dosing of off-label rituximab in multiple sclerosis: A real-world retrospective analysis of clinical efficacy and safety

This publication has 26 references indexed in Scilit:

• Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis
  Annals of Clinical and Translational Neurology, 2025
• Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: A systematic review and meta-analysis
  Neurological Sciences, 2025
• Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety
  Multiple Sclerosis and Related Disorders, 2025
• Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis
  Neurotherapeutics, 2025
• Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing – similar clinical efficacy with decreased immunoglobulin M deficiency rates
  Multiple Sclerosis and Related Disorders, 2023
• Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis
  Med, 2023
• The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis
  CNS Drugs, 2022
• Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
  Multiple Sclerosis and Related Disorders, 2022
• Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis
  Multiple Sclerosis and Related Disorders, 2020
• Serious safety events in rituximab‐treated multiple sclerosis and related disorders
  Annals of Clinical and Translational Neurology, 2020